Monday, 10 September 2018

U.S. appeals court invalidates Acorda patents on MS drug

A U.S. appeals court on Monday invalidated Acorda Therapeutics Inc patents covering its multiple sclerosis drug Ampyra, opening the door for generic competition for Acorda's flagship product.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)